cerca CERCA
Mercoledì 18 Maggio 2022
Aggiornato: 14:33
Temi caldi

Salute_E_Benessere Chimica_E_Farmacia Salute_E_Benessere Economia_E_Finanza

comunicato stampa

Discovery Life Sciences Streamlines Cell and Gene Therapy Manufacturing with Expanded Human Cellular Starting Materials

HUNTSVILLE, Ala., Feb. 17, 2022 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, today announced the expansion of its GMP-compliant, clinical- grade product portfolio with the launch of Discovery Cryo Leukopaks™ (GMP).  The company's extended capabilities around GMP-compliant cellular starting materials will ease logistical challenges for therapeutic developers and manufacturers by streamlining the transition from research to manufacturing of next-...

comunicato stampa

Ichnos Sciences Appoints Sonia Quaratino, M.D., Ph.D., To Its Board Of Directors

NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, announced that Sonia Quaratino, M.D., Ph.D., has been appointed as an independent member of its Board of Directors. Dr. Quaratino has over twenty-five years of experience in immunology research, clinical development at biotechnology and pharmaceutical companies, has served on multiple boards, and overseen research programs at leading acad...

comunicato stampa

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership.

comunicato stampa

Invenio Imaging receives CE Mark for NIO Laser Imaging System

SANTA CLARA, Calif., Sept. 28, 2021 /PRNewswire/ -- Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD). This enables commercialization of this novel imaging system for intraoperative histology in the European market.

comunicato stampa

Avidity Science Announces Agreement to Divest Lab Products & Harford Systems

WATERFORD, Wis., Sept. 3, 2021 /PRNewswire/ -- Avidity Science, a worldwide leader in life science research tools, today announces it has sold its subsidiaries of Lab Products, LLC and Harford Systems, LLC to Gen Cap America, Inc. ("Gen Cap"), a private equity firm focused on lower middle market buyouts.

comunicato stampa

Dr. Dominic Clarke Joins Discovery Life Sciences As Chief Technical Officer Of Cell And Gene Therapy

HUNTSVILLE, Ala., Aug. 12, 2021 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, announced today that Dominic Clarke, Ph.D. has joined the company as Chief Technical Officer of Cell & Gene Therapy.  His addition in this role will further establish Discovery as a global leader in cell and gene therapy materials and analytical services to support the development and manufacturing of advanced therapies.

BioAgilytix Welcomes Marc Westermann as Vice President of Business Development Europe to its Commercial Leadership Team

DURHAM, N.C., Jan. 4, 2021 /PRNewswire/ -- BioAgilytix Labs is pleased to announce the appointment of Marc Westermann to its commercial leadership team as Vice President of Business Development Europe. Westermann brings more than 25 years of senior corporate executive and commercial operations experience to BioAgilytix. He has a proven track record of leading performance within the broader pharmaceutical/biotech industry at organizations across five continents.

Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany

IRVINE, California, Oct. 6, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab in Leipzig, Germany. Breast cancer patients in Germany will now have access to state-of-the art genomic profiling in their own country.

ora in
Prima pagina
in Evidenza